Kiyohiro Houkin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kiyohiro Houkin has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Shigeru Yamaguchi
Department of Neurosurgery, Faculty of Medicine, Hokkaido University
15 shared publications - Yuuta Kamoshima
Department of Neurosurgery, Hokkaido University Graduate School of Medicine, Japan
11 shared publications - Masahito Kawabori
Department of Neurosurgery, Faculty of Medicine, Hokkaido University, Sapporo, Japan
8 shared publications Hiroyuki Kobayashi
Department of Neurosurgery, Kashiwaba Neurosurgical Hospital, Sapporo, Japan
7 shared publicationsHiroaki Motegi
Department of Neurosurgery, Hokkaido University Graduate School of Medicine, Japan
6 shared publications- Masaki Ito
Department of Neurosurgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan
5 shared publications
Latest Publications
- 1 October 2021
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 30 (10) , 106007
Efficacy of Carotid Artery Stenting Performed under General Anesthesia with Somatosensory Evoked Potential Monitoring
- 1 October 2021
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 30 (10) , 106007
Efficacy of Carotid Artery Stenting Performed under General Anesthesia with Somatosensory Evoked Potential Monitoring
- 1 August 2021
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 89, 148-150
Chronic deep brain stimulation reduces cortical β-γ phase amplitude-coupling in patients with Parkinson's disease
- 1 August 2021
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 89, 148-150
Chronic deep brain stimulation reduces cortical β-γ phase amplitude-coupling in patients with Parkinson's disease
- 1 June 2021
- Published by Elsevier in Journal Of Neuroradiology
- Vol. 48 (4) , 266-270
Correlation between magnetic resonance imaging characteristics and BRAF alteration status in individuals with optic pathway/hypothalamic pilocytic astrocytomas
- 1 June 2021
- Published by Elsevier in Journal Of Neuroradiology
- Vol. 48 (4) , 266-270
Correlation between magnetic resonance imaging characteristics and BRAF alteration status in individuals with optic pathway/hypothalamic pilocytic astrocytomas
- Open Access
- 4 May 2021
- Published by Wiley in Stem Cells International
- Vol. 2021, 1-2
Corrigendum to “Evaluation of Novel Stereotactic Cannula for Stem Cell Transplantation against Central Nervous System Disease”
In the article titled “Evaluation of Novel Stereotactic Cannula for Stem Cell Transplantation against Central Nervous System Disease” [1], there was an error in Table 1, where the unit for the outer diameter and internal bore diameter columns should be corrected to “μm.” In the internal volume column, the value “20 mL” should be corrected to “20 μL.”
- 4 May 2021
- Published by Wiley in Stem Cells International
- Vol. 2021, 1-2
Open AccessCorrigendum to “Evaluation of Novel Stereotactic Cannula for Stem Cell Transplantation against Central Nervous System Disease”
In the article titled “Evaluation of Novel Stereotactic Cannula for Stem Cell Transplantation against Central Nervous System Disease” [1], there was an error in Table 1, where the unit for the outer diameter and internal bore diameter columns should be corrected to “μm.” In the internal volume column, the value “20 mL” should be corrected to “20 μL.”
- 1 December 2020
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 29 (12) , 105305
Vascular Smooth Muscle Cell Derived from IPS Cell of Moyamoya Disease - Comparative Characterization with Endothelial Cell Transcriptome
- 1 December 2020
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 29 (12) , 105305
Vascular Smooth Muscle Cell Derived from IPS Cell of Moyamoya Disease - Comparative Characterization with Endothelial Cell Transcriptome
- Open Access
- 6 October 2020
- Published by Elsevier in Interdisciplinary Neurosurgery
- Vol. 23, 100951
Novel risk factors and management of brain sag after brain tumor surgery
- 6 October 2020
- Published by Elsevier in Interdisciplinary Neurosurgery
- Vol. 23, 100951
Open AccessNovel risk factors and management of brain sag after brain tumor surgery
- Open Access
- 6 October 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (19) , 7380
Clinical Trials of Stem Cell Therapy for Cerebral Ischemic Stroke
Despite recent developments in innovative treatment strategies, stroke remains one of the leading causes of death and disability worldwide. Stem cell therapy is currently attracting much attention due to its potential for exerting significant therapeutic effects on stroke patients. Various types of cells, including bone marrow mononuclear cells, bone marrow/adipose-derived stem/stromal cells, umbilical cord blood cells, neural stem cells, and olfactory ensheathing cells have enhanced neurological outcomes in animal stroke models. These stem cells have also been tested via clinical trials involving stroke patients. In this article, the authors review potential molecular mechanisms underlying neural recovery associated with stem cell treatment, as well as recent advances in stem cell therapy, with particular reference to clinical trials and future prospects for such therapy in treating stroke.
- 6 October 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (19) , 7380
Open AccessClinical Trials of Stem Cell Therapy for Cerebral Ischemic Stroke
Despite recent developments in innovative treatment strategies, stroke remains one of the leading causes of death and disability worldwide. Stem cell therapy is currently attracting much attention due to its potential for exerting significant therapeutic effects on stroke patients. Various types of cells, including bone marrow mononuclear cells, bone marrow/adipose-derived stem/stromal cells, umbilical cord blood cells, neural stem cells, and olfactory ensheathing cells have enhanced neurological outcomes in animal stroke models. These stem cells have also been tested via clinical trials involving stroke patients. In this article, the authors review potential molecular mechanisms underlying neural recovery associated with stem cell treatment, as well as recent advances in stem cell therapy, with particular reference to clinical trials and future prospects for such therapy in treating stroke.
- Open Access
- 6 July 2020
- Published by SAGE Publications in Journal of Neurotrauma
- Vol. 37 (15) , 1720-1728
FTY720 Attenuates Neuropathic Pain after Spinal Cord Injury by Decreasing Systemic and Local Inflammation in a Rat Spinal Cord Compression Model
Neuropathic pain severely impairs rehabilitation and quality of life after spinal cord injury (SCI). The sphingosine-1-phosphate receptor agonist, FTY720, plays an important protective role in neuronal injury. This study aims to examine the effects of FTY720 in a rat acute SCI model, focusing on neuropathic pain. Female rats with SCI induced by 1-min clip compression were administered vehicle or 1.5 mg/kg of FTY720 24 h after the injury. Using the mechanical nociceptive threshold test, we monitored neuropathic pain and performed histological analysis of the pain pathway, including the μ opioid receptor (MOR), hydroxytryptamine transporter (HTT), and calcitonin gene-related peptide (CGRP). Motor score, SCI lesion volume, residual motor axons, inflammatory response, glial scar, and microvascular endothelial dysfunction were also compared between the two groups. FTY720 treatment resulted in significant attenuation of post-traumatic neuropathic pain. It also decreased systemic and local inflammation, thereby reducing the damaged areas and astrogliosis and resulting in motor functional recovery. Whereas there was no difference in the CGRP expression between the two groups, FTY720 significantly preserved the MOR in both the caudal and rostral areas of the spinal dorsal horn. Whereas HTT was preserved in the FTY720 group, it was significantly increased in the rostral side and decreased in the caudal side of the injury in the vehicle group. These results suggest that FTY720 ameliorates post-traumatic allodynia through regulation of neuroinflammation, maintenance of the blood–brain barrier, and inhibition of glial scar formation, thereby preserving the connectivity of the descending inhibitory pathway and reducing neuropathic pain.
- 6 July 2020
- Published by SAGE Publications in Journal of Neurotrauma
- Vol. 37 (15) , 1720-1728
Open AccessFTY720 Attenuates Neuropathic Pain after Spinal Cord Injury by Decreasing Systemic and Local Inflammation in a Rat Spinal Cord Compression Model
Neuropathic pain severely impairs rehabilitation and quality of life after spinal cord injury (SCI). The sphingosine-1-phosphate receptor agonist, FTY720, plays an important protective role in neuronal injury. This study aims to examine the effects of FTY720 in a rat acute SCI model, focusing on neuropathic pain. Female rats with SCI induced by 1-min clip compression were administered vehicle or 1.5 mg/kg of FTY720 24 h after the injury. Using the mechanical nociceptive threshold test, we monitored neuropathic pain and performed histological analysis of the pain pathway, including the μ opioid receptor (MOR), hydroxytryptamine transporter (HTT), and calcitonin gene-related peptide (CGRP). Motor score, SCI lesion volume, residual motor axons, inflammatory response, glial scar, and microvascular endothelial dysfunction were also compared between the two groups. FTY720 treatment resulted in significant attenuation of post-traumatic neuropathic pain. It also decreased systemic and local inflammation, thereby reducing the damaged areas and astrogliosis and resulting in motor functional recovery. Whereas there was no difference in the CGRP expression between the two groups, FTY720 significantly preserved the MOR in both the caudal and rostral areas of the spinal dorsal horn. Whereas HTT was preserved in the FTY720 group, it was significantly increased in the rostral side and decreased in the caudal side of the injury in the vehicle group. These results suggest that FTY720 ameliorates post-traumatic allodynia through regulation of neuroinflammation, maintenance of the blood–brain barrier, and inhibition of glial scar formation, thereby preserving the connectivity of the descending inhibitory pathway and reducing neuropathic pain.
- Open Access
- 2 June 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (11) , 3994
Clinical Trials of Stem Cell Treatment for Spinal Cord Injury
There are more than one million patients worldwide suffering paralysis caused by spinal cord injury (SCI). SCI causes severe socioeconomic problems not only to the patients and their caregivers but also to society; therefore, the development of innovative treatments is crucial. Many pharmacological therapies have been attempted in an effort to reduce SCI-related damage; however, no single therapy that could dramatically improve the serious long-term sequelae of SCI has emerged. Stem cell transplantation therapy, which can ameliorate damage or regenerate neurological networks, has been proposed as a promising candidate for SCI treatment, and many basic and clinical experiments using stem cells for SCI treatment have been launched, with promising results. However, the cell transplantation methods, including cell type, dose, transplantation route, and transplantation timing, vary widely between trials, and there is no consensus regarding the most effective treatment strategy. This study reviews the current knowledge on this issue, with a special focus on the clinical trials that have used stem cells for treating SCI, and highlights the problems that remain to be solved before the widespread clinical use of stem cells can be adopted.
- 2 June 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (11) , 3994
Open AccessClinical Trials of Stem Cell Treatment for Spinal Cord Injury
There are more than one million patients worldwide suffering paralysis caused by spinal cord injury (SCI). SCI causes severe socioeconomic problems not only to the patients and their caregivers but also to society; therefore, the development of innovative treatments is crucial. Many pharmacological therapies have been attempted in an effort to reduce SCI-related damage; however, no single therapy that could dramatically improve the serious long-term sequelae of SCI has emerged. Stem cell transplantation therapy, which can ameliorate damage or regenerate neurological networks, has been proposed as a promising candidate for SCI treatment, and many basic and clinical experiments using stem cells for SCI treatment have been launched, with promising results. However, the cell transplantation methods, including cell type, dose, transplantation route, and transplantation timing, vary widely between trials, and there is no consensus regarding the most effective treatment strategy. This study reviews the current knowledge on this issue, with a special focus on the clinical trials that have used stem cells for treating SCI, and highlights the problems that remain to be solved before the widespread clinical use of stem cells can be adopted.
- Open Access
- 29 August 2018
- Published by Springer Nature in BMC Medical Genomics
- Vol. 11 (1) , 1-10
Circulating miRNome profiling in Moyamoya disease-discordant monozygotic twins and endothelial microRNA expression analysis using iPS cell line
Moyamoya disease (MMD) is characterized by progressive stenosis of intracranial arteries in the circle of Willis with unknown etiology even after the identification of a Moyamoya susceptible gene, RNF213. Recently, differences in epigenetic regulations have been investigated by a case-control study in MMD. Here, we employed a disease discordant monozygotic twin-based study design to unmask potential confounders. Circulating genome-wide microRNA (miRNome) profiling was performed in MMD-discordant monozygotic twins, non-twin-MMD patients, and non-MMD healthy volunteers by microarray followed by qPCRvalidation, using blood samples. Differential plasma-microRNAs were further quantified in endothelial cells differentiated from iPS cell lines (iPSECs) derived from another independent non-twin cohort. Lastly, their target gene expression in the iPSECs was analyzed. Microarray detected 309 plasma-microRNAs in MMD-discordant monozygotic twins that were also detected in the non-twin cohort. Principal component analysis of the plasma-microRNA expression level demonstrated distinct 2 groups separated by MMD and healthy control in the twin- and non-twin cohorts. Of these, differential upregulations of hsa-miR-6722-3p/− 328-3p were validated in the plasma of MMD (absolute log2 expression fold change (logFC) > 0.26 for the twin cohort; absolute logFC > 0.26, p < 0.05, and q < 0.15 for the non-twin cohort). In MMD derived iPSECs, hsa-miR-6722-3p/− 328-3p showed a trend of up-regulation with a 3.0- or higher expression fold change. Bioinformatics analysis revealed that 41 target genes of miR-6722-3p/− 328-3p were significantly down-regulated in MMD derived iPSECs and were involved in STAT3, IGF-1-, and PTEN-signaling, suggesting a potential microRNA-gene expression interaction between circulating plasma and endothelial cells. Our MMD-discordant monozygotic twin-based study confirmed a novel circulating microRNA signature in MMD as a potential diagnostic biomarker minimally confounded by genetic heterogeneity. The novel circulating microRNA signature can contribute for the future functional microRNA analysis to find new diagnostic and therapeutic target of MMD.
- 29 August 2018
- Published by Springer Nature in BMC Medical Genomics
- Vol. 11 (1) , 1-10
Open AccessCirculating miRNome profiling in Moyamoya disease-discordant monozygotic twins and endothelial microRNA expression analysis using iPS cell line
Moyamoya disease (MMD) is characterized by progressive stenosis of intracranial arteries in the circle of Willis with unknown etiology even after the identification of a Moyamoya susceptible gene, RNF213. Recently, differences in epigenetic regulations have been investigated by a case-control study in MMD. Here, we employed a disease discordant monozygotic twin-based study design to unmask potential confounders. Circulating genome-wide microRNA (miRNome) profiling was performed in MMD-discordant monozygotic twins, non-twin-MMD patients, and non-MMD healthy volunteers by microarray followed by qPCRvalidation, using blood samples. Differential plasma-microRNAs were further quantified in endothelial cells differentiated from iPS cell lines (iPSECs) derived from another independent non-twin cohort. Lastly, their target gene expression in the iPSECs was analyzed. Microarray detected 309 plasma-microRNAs in MMD-discordant monozygotic twins that were also detected in the non-twin cohort. Principal component analysis of the plasma-microRNA expression level demonstrated distinct 2 groups separated by MMD and healthy control in the twin- and non-twin cohorts. Of these, differential upregulations of hsa-miR-6722-3p/− 328-3p were validated in the plasma of MMD (absolute log2 expression fold change (logFC) > 0.26 for the twin cohort; absolute logFC > 0.26, p < 0.05, and q < 0.15 for the non-twin cohort). In MMD derived iPSECs, hsa-miR-6722-3p/− 328-3p showed a trend of up-regulation with a 3.0- or higher expression fold change. Bioinformatics analysis revealed that 41 target genes of miR-6722-3p/− 328-3p were significantly down-regulated in MMD derived iPSECs and were involved in STAT3, IGF-1-, and PTEN-signaling, suggesting a potential microRNA-gene expression interaction between circulating plasma and endothelial cells. Our MMD-discordant monozygotic twin-based study confirmed a novel circulating microRNA signature in MMD as a potential diagnostic biomarker minimally confounded by genetic heterogeneity. The novel circulating microRNA signature can contribute for the future functional microRNA analysis to find new diagnostic and therapeutic target of MMD.